Fentanyl and clonidine
PreclinicalSmall molecule
Fentanyl and clonidine is one of 17 small molecule programs targeting Hypothermia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Hypothermia
#DrugCompanyPhaseTrials
1Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Paracetamol
GSKApproved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Epsom Salt
FFresenius Kabi Oncology Ltd.
Phase 3
Xe-133
NNobilis Therapeutics Inc.
Phase 2
Enbrel
IImmunex
Phase 2
Fentanyl and Midazolam
NNorwegian University of Science and Technology
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 1
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 1
Neuromuscular Blocking Agents
UUniversity of Maryland, Baltimore
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fentanyl and clonidine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRegion Skane